Study of MM-398 as front-line therapy in patients with HER2-negative gastric cancer
Phase of Trial: Phase III
Latest Information Update: 17 Nov 2015
At a glance
- Drugs Irinotecan (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 17 Nov 2015 Planned initiation date changed from 1 Jun 2015 to 1 Mar 2016.
- 09 Nov 2015 According to a Merrimack Pharmaceuticals media release, this trial will commence in 2016.
- 11 May 2015 New trial record